Avadel Pharma (AVDL) Tops Q2 EPS by 4c

Avadel Pharma (NASDAQ: AVDL) reported Q2 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $37.47 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Five Below (FIVE) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY27 Guidance
• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform